Table 3.
Baseline characteristics and association with survival outcomes
| Characteristics | N | % | Median PFS (months) | HR (95% CI), p value | Median OS (months) | HR (95% CI), p value |
|---|---|---|---|---|---|---|
| Overall cohort | 40 | 100 | 15.6 | 44.6 | ||
| Sex | ||||||
| • Male | 24 | 60.0 | 14.3 | 0.473 (0.205–1.092) | 43.7 | 0.591 (0.267–1.308) |
| • Female | 16 | 40.0 | 45.3 | p = 0.080 | 51.3 | p = 0.194 |
| Age | ||||||
| • < 60 | 20 | 50.0% | 15.4 | 0.691 (0.317–1.509) | 43.1 | 0.569 (0.264–1.223) |
| • > 60 | 20 | 50.0% | 16.0 | p = 0.354 | 63.1 | p = 0.149 |
| T stage | ||||||
| • T3 | 16 | 40.0% | 14.4 | 0.975 (0.413–2.299) | 51.3 | 1.363 (0.581–3.194) |
| • T4 | 18 | 45.0% | 25.5 | p = 0.954 | 44.6 | p = 0.477 |
| N stage | ||||||
| • N1 | 16 | 40.0% | 13.3 | 1.108 (0.564–2.175) | 43.7 | 0.978 (0.516–1.852) |
| • N2 | 17 | 42.5% | 16.0 | p = 0.767 | 61.7 | p = 0.945 |
| Serum CEA level at diagnosis | ||||||
| • Normal | 19 | 47.5% | 48.7 | 2.879 (1.269–6.534) | 74.2 | 2.355 (1.081–5.133) |
| • Raised | 21 | 52.5% | 12.1 | p = 0.011 | 41.4 | p = 0.031 |
| Metastatic sites | ||||||
| • Single | 22 | 55.0% | 16.1 | 1.090 (0.504–2.361) | 44.2 | 0.869 (0.406–1.859) |
| • Multiple | 18 | 45.0% | 14.4 | p = 0.826 | 51.4 | p = 0.717 |